Tomita D - Search Results

1

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials.

Revicki DA, Stull D, Vernon M, Rader M, Tomita D, Viswanathan HN. Revicki DA, et al. Among authors: tomita d. Qual Life Res. 2012 Mar;21(2):311-21. doi: 10.1007/s11136-011-9946-z. Epub 2011 Jun 5. Qual Life Res. 2012. PMID: 21644007

2

The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.

Boccia R, Lillie T, Tomita D, Balducci L. Boccia R, et al. Among authors: tomita d. Oncologist. 2007 May;12(5):584-93. doi: 10.1634/theoncologist.12-5-584. Oncologist. 2007. PMID: 17522247 Free article. Clinical Trial.

3

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.

Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C. Gordon D, et al. Among authors: tomita d. Oncologist. 2008 Jun;13(6):715-24. doi: 10.1634/theoncologist.2007-0241. Oncologist. 2008. PMID: 18586927 Free article. Clinical Trial.

4

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.

Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P. Boccia R, et al. Among authors: tomita d. Oncologist. 2006 Apr;11(4):409-17. doi: 10.1634/theoncologist.11-4-409. Oncologist. 2006. PMID: 16614237 Free article.

5

A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.

Gascón P, Nagarkar R, Šmakal M, Syrigos KN, Barrios CH, Sánchez JC, Zhang L, Henry DH, Gordon D, Hirsh V, Kubota K, Orlov S, Thomas G, Steinmetz T, Kang JH, Tomita DK, Fleishman AN, Park JK, De Oliveira Brandao C. Gascón P, et al. Among authors: tomita dk. J Thorac Oncol. 2020 Feb;15(2):190-202. doi: 10.1016/j.jtho.2019.10.005. Epub 2019 Oct 16. J Thorac Oncol. 2020. PMID: 31629060 Free article. Clinical Trial.

6

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP. Mirtsching B, et al. Among authors: tomita d. Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):31-6. Oncology (Williston Park). 2002. PMID: 12435171 Clinical Trial.

7

Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.

Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, Schwartzberg L. Senecal FM, et al. Among authors: tomita d. Clin Breast Cancer. 2005 Dec;6(5):446-54. doi: 10.3816/cbc.2005.n.050. Clin Breast Cancer. 2005. PMID: 16381629 Clinical Trial.

8

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.

Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A. Charu V, et al. Among authors: tomita d. Oncologist. 2007 Jun;12(6):727-37. doi: 10.1634/theoncologist.12-6-727. Oncologist. 2007. PMID: 17602062 Free article. Clinical Trial.

9

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.

Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. Charu V, et al. Among authors: tomita d. Oncologist. 2007 Oct;12(10):1253-63. doi: 10.1634/theoncologist.12-10-1253. Oncologist. 2007. PMID: 17962619 Free article. Clinical Trial.

10

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.

20030125 Study Group Trial; Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. 20030125 Study Group Trial, et al. Among authors: tomita d. J Clin Oncol. 2006 May 20;24(15):2290-7. doi: 10.1200/JCO.2005.03.8570. J Clin Oncol. 2006. PMID: 16710026 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page